Here, we investigated the effect of prophylactic oral treatment with carbonate apatite‐based particles (ID35caps) containing Lactobacillus rhamnosus GG‐derived immunostimulatory oligodeoxynucleotides (ID35) when used in mice with acute colitis. Mice were administered orally with control particles (carbonate apatite particles, Caps), ID35, or ID35caps for 2 days, and then were given free access to drinking water containing 3% (w/v) dextran sodium sulfate (DSS) for 5 days (Days 0–5) to induce acute colitis. Body weight change, fecal bleeding, and stool consistency were monitored and scored as a disease activity index (DAI) to assess symptoms of colitis. On Day 10, animals were euthanized and the colon length was measured to evaluate inflammatory tissue injury. Prophylactic oral treatment with ID35caps significantly suppressed DSS‐induced elevation of the DAI score and shortening of the colon compared to the respective parameters in DSS‐exposed mice treated with Cap or ID35. We conclude that oral priming with ID35caps attenuates symptoms and inflammatory colonic injury in a mouse model of DSS‐induced acute colitis. This finding suggests that ID35caps may be a new oral agent for preventing intestinal inflammation.

中文翻译：

---

口服鼠李糖乳杆菌 GG 寡脱氧核苷酸颗粒可减轻右旋糖酐硫酸钠诱导的小鼠急性结肠炎症状

在这里，我们研究了含有鼠李糖乳杆菌的碳酸盐磷灰石颗粒 (ID35caps) 进行预防性口服治疗的效果GG 衍生的免疫刺激性寡脱氧核苷酸 (ID35) 用于患有急性结肠炎的小鼠。给小鼠口服对照颗粒（碳酸盐磷灰石颗粒，Caps）、ID35 或 ID35caps 2 天，然后自由饮用含有 3% (w/v) 葡聚糖硫酸钠 (DSS) 的饮用水 5 天（第 0–5 天）诱发急性结肠炎。监测体重变化、粪便出血和粪便稠度，并将其作为疾病活动指数 (DAI) 进行评分，以评估结肠炎的症状。在第 10 天，动物被安乐死并测量结肠长度以评估炎症组织损伤。与用 Cap 或 ID35 处理的暴露于 DSS 的小鼠的相应参数相比，用 ID35caps 预防性口服治疗显着抑制了 DSS 诱导的 DAI 评分升高和结肠缩短。我们得出结论，在 DSS 诱导的急性结肠炎小鼠模型中，口服 ID35caps 可减轻症状和炎症性结肠损伤。这一发现表明 ID35caps 可能是一种预防肠道炎症的新型口服药物。